VRXA (Veraxa Biotech Holding AG) Other Long-Term Liabilities: $12.05 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VRXA Veraxa Biotech Holding AG VRXA
6 GF Score
Price $1.50
! 3 Warning Signs
View Full Analysis

What is Veraxa Biotech Holding AG Other Long-Term Liabilities?

Veraxa Biotech Holding AG VRXA -1.32% 6 Other Long-Term Liabilities is $12.05 Mil as of Dec. 2025. GuruFocus rates VRXA with a GF Score™ of 6/100. The stock has 3 warning signs investors should review.

Veraxa Biotech Holding AG's other long-term liabilities for the quarter that ended in Dec. 2025 was $12.05 Mil.

Veraxa Biotech Holding AG's quarterly other long-term liabilities stayed the same from Dec. 2024 ($12.05 Mil) to Jun. 2025 ($12.05 Mil) and stayed the same from Jun. 2025 ($12.05 Mil) to Dec. 2025 ($12.05 Mil).

Veraxa Biotech Holding AG's annual other long-term liabilities increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($12.05 Mil) but then stayed the same from Dec. 2024 ($12.05 Mil) to Dec. 2025 ($12.05 Mil).

Veraxa Biotech Holding AG Other Long-Term Liabilities Related Terms

Veraxa Biotech Holding AG Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Veraxa Biotech Holding AG's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veraxa Biotech Holding AG Other Long-Term Liabilities Chart

Veraxa Biotech Holding AG Annual Data
Trend Dec23 Dec24 Dec25
Other Long-Term Liabilities
0.00 12.05 12.05

Veraxa Biotech Holding AG Quarterly Data
Jun24 Dec24 Jun25 Dec25
Other Long-Term Liabilities 0.00 12.05 12.05 12.05
VRXA
6GF Score
Veraxa Biotech Holding AG VRXA
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veraxa Biotech Holding AG Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $12.05 Mil mean?
Veraxa Biotech Holding AG (VRXA) has a Other Long-Term Liabilities of $12.05 Mil as of Dec. 2025. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Veraxa Biotech Holding AG and its competitors.
Is Veraxa Biotech Holding AG's Other Long-Term Liabilities too high?
Veraxa Biotech Holding AG's current Other Long-Term Liabilities is $12.05 Mil. Overall, Veraxa Biotech Holding AG has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Veraxa Biotech Holding AG's Other Long-Term Liabilities compare to KRRO and CNXU?
Veraxa Biotech Holding AG's Other Long-Term Liabilities of $12.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Veraxa Biotech Holding AG and its competitors. Veraxa Biotech Holding AG's current Other Long-Term Liabilities is $12.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veraxa Biotech Holding AG stock overvalued right now?
Veraxa Biotech Holding AG (VRXA) has a current Other Long-Term Liabilities of $12.05 Mil. The current Other Long-Term Liabilities is $12.05 Mil. Veraxa Biotech Holding AG's overall GF Score™ is 6/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Veraxa Biotech Holding AG (VRXA), the current Other Long-Term Liabilities is $12.05 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Veraxa Biotech Holding AG Business Description

Other Exchanges J8L0:Germany
Address Talacker 35, Zurich, CHE, 8001
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
6GF Score

Get the complete analysis for VRXA

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.50
Price